515 related articles for article (PubMed ID: 31754786)
1. [Treatment of systemic sclerosis-associated interstitial lung disease].
Prasse A; Bonella F; Müller-Ladner U; Witte T; Hunzelmann N; Distler J
Z Rheumatol; 2020 Apr; 79(3):294-303. PubMed ID: 31754786
[TBL] [Abstract][Full Text] [Related]
2. Interstitial lung disease in systemic sclerosis.
Bussone G; Mouthon L
Autoimmun Rev; 2011 Mar; 10(5):248-55. PubMed ID: 20863911
[TBL] [Abstract][Full Text] [Related]
3. Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease.
Distler O; Volkmann ER; Hoffmann-Vold AM; Maher TM
Expert Rev Clin Immunol; 2019 Oct; 15(10):1009-1017. PubMed ID: 31566449
[No Abstract] [Full Text] [Related]
4. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.
Yamasaki Y; Kuwana M
Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975
[TBL] [Abstract][Full Text] [Related]
5. Interstitial lung disease associated with systemic sclerosis (SSc-ILD).
Cottin V; Brown KK
Respir Res; 2019 Jan; 20(1):13. PubMed ID: 30658650
[TBL] [Abstract][Full Text] [Related]
6. Management of systemic sclerosis-associated interstitial lung disease.
Roofeh D; Jaafar S; Vummidi D; Khanna D
Curr Opin Rheumatol; 2019 May; 31(3):241-249. PubMed ID: 30870216
[TBL] [Abstract][Full Text] [Related]
7. [Interstitial lung disease in rheumatic diseases - new therapeutic approaches].
Jakubczyc A; Neurohr C
Dtsch Med Wochenschr; 2020 Apr; 145(7):470-473. PubMed ID: 32236928
[TBL] [Abstract][Full Text] [Related]
8. Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease.
Higuero Sevilla JP; Memon A; Hinchcliff M
Arthritis Res Ther; 2023 Jul; 25(1):118. PubMed ID: 37422652
[TBL] [Abstract][Full Text] [Related]
9. Interstitial lung disease in systemic sclerosis: current and future treatment.
Giacomelli R; Liakouli V; Berardicurti O; Ruscitti P; Di Benedetto P; Carubbi F; Guggino G; Di Bartolomeo S; Ciccia F; Triolo G; Cipriani P
Rheumatol Int; 2017 Jun; 37(6):853-863. PubMed ID: 28063071
[TBL] [Abstract][Full Text] [Related]
10. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
[TBL] [Abstract][Full Text] [Related]
11. Management of systemic sclerosis: the first five years.
Roofeh D; Khanna D
Curr Opin Rheumatol; 2020 May; 32(3):228-237. PubMed ID: 32205570
[TBL] [Abstract][Full Text] [Related]
12. Interstitial Lung Disease: How Should Therapeutics Be Implemented?
Bruni C; Campochiaro C; de Vries-Bouwstra JK
Rheum Dis Clin North Am; 2023 May; 49(2):279-293. PubMed ID: 37028835
[TBL] [Abstract][Full Text] [Related]
13. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
Front Immunol; 2020; 11():1990. PubMed ID: 33013852
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological treatment of systemic sclerosis-associated interstitial lung disease: an updated review and current approach to patient care.
Mendoza FA; Allawh T; Jimenez SA
Clin Exp Rheumatol; 2023 Aug; 41(8):1704-1712. PubMed ID: 37382458
[TBL] [Abstract][Full Text] [Related]
15. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
Rahaghi FF; Hsu VM; Kaner RJ; Mayes MD; Rosas IO; Saggar R; Steen VD; Strek ME; Bernstein EJ; Bhatt N; Castelino FV; Chung L; Domsic RT; Flaherty KR; Gupta N; Kahaleh B; Martinez FJ; Morrow LE; Moua T; Patel N; Shlobin OA; Southern BD; Volkmann ER; Khanna D
Respir Res; 2023 Jan; 24(1):6. PubMed ID: 36624431
[TBL] [Abstract][Full Text] [Related]
16. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G;
Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380
[TBL] [Abstract][Full Text] [Related]
17. [Modern drug therapy for systemic sclerosis associated interstitial lung disease].
Aringer M; Koschel D; Krause A; Schneider U; Gläser S
Dtsch Med Wochenschr; 2022 Feb; 147(4):179-186. PubMed ID: 34861699
[TBL] [Abstract][Full Text] [Related]
18. [Interstitial lung disease in systemic sclerosis].
Mouthon L; Berezné A; Brauner M; Kambouchner M; Guillevin L; Valeyre D
Presse Med; 2006 Dec; 35(12 Pt 2):1943-51. PubMed ID: 17159721
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.
Raghu G; Montesi SB; Silver RM; Hossain T; Macrea M; Herman D; Barnes H; Adegunsoye A; Azuma A; Chung L; Gardner GC; Highland KB; Hudson M; Kaner RJ; Kolb M; Scholand MB; Steen V; Thomson CC; Volkmann ER; Wigley FM; Burlile D; Kemper KA; Knight SL; Ghazipura M
Am J Respir Crit Care Med; 2024 Jan; 209(2):137-152. PubMed ID: 37772985
[No Abstract] [Full Text] [Related]
20. Systemic Sclerosis Associated Interstitial Lung Disease and Nintedanib: A Rare Disease and a Promising Drug.
Kafle S; Thapa Magar M; Patel P; Poudel A; Cancarevic I
Cureus; 2021 Jul; 13(7):e16404. PubMed ID: 34414042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
